Telix Pharmaceuticals Shares Surge 7% After Outperforming FY24 Guidance

2 min read | January 14, 2025 11:45 AM AEDT | By Team Kalkine Media

Telix Pharmaceuticals Shares Surge 7% After Outperforming FY24 Guidance — Image source: Shutterstock

Strong Revenue Growth

Telix reported unaudited fourth-quarter revenue of approximately US$142 million (AU$218 million), reflecting a 46% year-on-year increase and a 5% quarter-on-quarter growth. Full-year unaudited revenue came in at US$517 million (AU$783 million), exceeding the company’s guidance range of US$490 million to US$510 million. This represents a 55% year-on-year revenue increase, primarily driven by robust sales of Illuccix, a diagnostic radiopharmaceutical used for prostate cancer PET imaging.

Strategic Investments and Milestones

Telix noted that its ongoing investment in research and development (R&D) remains aligned with its guidance and is fully funded by earnings from product sales. The company has achieved several significant milestones in 2024, including a strengthened balance sheet, a Nasdaq listing, and the acquisition of fibroblast activation protein (FAP)-targeting assets to enhance its product pipeline.

Dr. Christian Behrenbruch, managing director and CEO of Telix, praised the company’s performance, stating:
"Strong sales of Illuccix have led Telix to close out the year with revenue above guidance, while significantly progressing our strategic priorities. 2025 is shaping up to be a transformative year for Telix."

Future Growth Opportunities

Telix is poised for expansion in 2025, with plans to launch multiple imaging products in key markets and advance late-stage therapeutic assets into pivotal trials. These include:

TLX101 (glioblastoma therapy): Telix is preparing for an investigational new drug (IND) submission in the first half of 2025, following positive feedback from the US FDA.
TLX250 (kidney cancer therapy): Development efforts continue for this promising candidate.
TLX591 (prostate cancer therapy): Advancements are planned for this therapy as part of the company’s late-stage pipeline.

Telix plans to release its FY25 guidance alongside audited FY24 results on February 20, 2025.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.